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lamotrigine and topiramate as adjunctive therapy in the treat-
ment of LGS from a UK NHS perspective was assessed.
METHODS: A semi-Markov model with individual patient
simulation was developed to estimate the costs and clinical ben-
eﬁts of the newer antiepileptic drugs over a 3 year time horizon.
The outcome measure is the percentage of successfully treated
patients, with success deﬁned as50% reduction in frequency of
drop attacks. In the absence of head-to-head clinical trials, indi-
rect comparisons were made among the alternative therapies
using placebo as the common comparator. Health states applied
in the model were >75% reduction in seizure frequency, 50%–
75% reduction, <50% reduction and death. Transition prob-
abilities were derived from patient level trial data on ruﬁnamide
and published clinical trials for the comparators. Estimates for
resource use were derived from interviews with 5 practicing
paediatric epileptologists, to which published UK unit costs were
applied. Results of 10,000 Monte Carlo simulations were boot-
strapped to conduct probabilistic sensitivity analysis. RESULTS:
Over 3 years 11.3% of ruﬁnamide patients were treated success-
fully compared to 7.2% and 5.2% with topiramate and lamot-
rigine respectively. Total discounted costs of treatments were
respectively £50,985, £50,730 and £50,975 with a highly right-
skewed distribution. Mean incremental cost-effectiveness ratios
(ICER) for ruﬁnamide were £6,215 (90%CI: dominant–
£40,000) and £172 (dominant -£19,100) per 1% increase in
success rate versus topiramate and lamotrigine respectively. At
£13,000 per 1% increase in successfully treated patients over 3
years ruﬁnamide is has the highest probability of being cost-
effective. Shorter time horizons and higher hospitalisation rates
improved the cost-effectiveness of ruﬁnamide. CONCLUSION:
Ruﬁnamide is a cost-effective therapy compared to topiramate
and lamotrigine as adjunctive therapy in achieving greater than
50% reduction in frequency of drop attacks in LGS.
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OBJECTIVES: To assess the scientiﬁc literature for studies evalu-
ating comparative economic value of the ﬁve disease modifying
drugs (DMDs) approved in the United States (U.S.) for the
management of relapsing forms of multiple sclerosis (MS).
METHODS: A comprehensive search of the MEDLINE data-
base, as well as the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) and Academy of Managed
Care Pharmacy (AMCP) meeting proceedings was conducted to
identify cost effectiveness (CE) analysis studies published or pre-
sented from 2004 through May 2007. Studies were critically
reviewed with regard to evaluated comparators, primary end-
points, measures of relapse reduction, perspective, timeframe,
and cost of therapy. RESULTS: The two identiﬁed CE analyses
both utilized cost per relapse avoided as the primary endpoint,
but the results varied signiﬁcantly in terms of CE ratios and
relative DMD rankings. The primary determinant of these varia-
tions was the methodology used to calculate relapse reduction
from the data reported in randomized placebo-controlled trials.
While the same clinical trials were employed by both models, the
number of avoided relapses was based on absolute reduction in
the case of Goldberg et al and on relative reduction in the case of
Chiao et al, and the models used different assumptions with
respect to timeframe, treatment adherence, monitoring costs,
contractual discounts, and member co-payments. Due to the
limitations inherent to the relative event reduction methodology,
the model developed by Chiao et al was highly sensitive to the
variation in the average relapse rate prior to treatment. CON-
CLUSION: The choice of methodology used to calculate thera-
peutic impact on relapse reduction can signiﬁcantly inﬂuence the
outcome of CE analyses. Considering signiﬁcant heterogeneity in
baseline disease severity among clinical trials in MS, use of abso-
lute reduction in relapse rate may be more appropriate as it more
accurately reﬂects the net clinical beneﬁt.
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OBJECTIVES: The EVidence of Interferon Dose-response Euro-
pean North American Comparative Efﬁcacy (EVIDENCE) trial
concluded administering subcutaneous (SC) IFNb1a 44 micro-
grams three times per week was more effective in improving the
proportion with relapsing form of multiple sclerosis (RFMS)
remaining relapse-free than intramuscular (IM) 30 micrograms
weekly after 24 and 48 weeks. This analysis utilized discrete
event simulation (DES) to model the potential longer-term clini-
cal and economic implications of this trial. METHODS: This
DES predicts the course of RFMS, reads in actual patient proﬁles
from the trial and creates two hypothetical cohorts—one receives
SC IFNb1a and the other IM. Patients may suffer relapses with
short- and long-term impact on costs and disability, develop new
T2 lesions, discontinue treatment, progress to secondary progres-
sive MS (SPMS) or die. Risk equations were derived from speciﬁc
analyses of trial data for relapse and supplemented with pub-
lished studies for SPMS and death. Direct medical costs to US
payers obtained from literature and databases were reported in
2006 USD and discounted at 3%. Extensive sensitivity analyses
were conducted. RESULTS: Based on 100 replications of 1000
patient pairs over four years, SC administration was predicted to
allow more patients to avoid a relapse (216 vs. 147). Total mean
costs per patient were $79,154 with SC vs. $73,820 with IM, a
net increase of $5335. SC IFNb1a was estimated to give a mean
of 0.50 relapses prevented, and 23 relapse-free days gained per
patient, yielding incremental cost effectiveness ratios of $10,616
per relapse prevented and $229 per relapse-free day gained.
Sensitivity analyses revealed that the result was most sensitive to
the cost of treatment, criteria for response, and treatment dura-
tion before assessing response. CONCLUSION: SC IFNb1a is
predicted to improve health outcomes over four years for a cost
that would seem an acceptable trade off.
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OBJECTIVES: To assess the cost-effectiveness of using a
lidocaine 5% medicated plaster in place of gabapentin (1800 mg/
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